Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRRX DURECT	$1.94 +1.0%	$1.10	$0.48 ▼ $2.64	$59.62M	0.83	3.13 million shs	597,750 shs
IFRX InflaRx	$0.92 +0.8%	$0.85	$0.71 ▼ $2.82	$61.33M	1.29	238,088 shs	505,989 shs
MTVA MetaVia	$0.65 0.0%	$0.66	$0.56 ▼ $4.32	$15.73M	0.26	316,569 shs	17,802 shs
PRLD Prelude Therapeutics	$1.27 +2.4%	$0.87	$0.61 ▼ $5.64	$71.88M	1.22	193,643 shs	634,228 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRRX DURECT	0.00%	+0.52%	+238.39%	+252.94%	+34.27%
IFRX InflaRx	0.00%	+5.86%	+1.65%	-50.62%	-42.18%
MTVA MetaVia	0.00%	+1.56%	-7.81%	-17.70%	+64,999,900.00%
PRLD Prelude Therapeutics	0.00%	+42.53%	+33.33%	+39.92%	-76.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRRX DURECT	2.1782 of 5 stars	0.0	5.0	4.4	4.2	0.0	0.0
IFRX InflaRx	2.635 of 5 stars	3.5	4.0	0.0	1.1	1.7	0.6
MTVA MetaVia	2.497 of 5 stars	3.5	0.0	0.0	3.2	0.0	1.3
PRLD Prelude Therapeutics	2.7804 of 5 stars	3.5	3.0	0.0	0.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRRX DURECT	2.00	Hold	N/A	N/A
IFRX InflaRx	3.00	Buy	$6.60	616.69% Upside
MTVA MetaVia	3.00	Buy	$7.50	1,054.02% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.00	214.96% Upside

Current Analyst Ratings Breakdown

Latest MTVA, IFRX, PRLD, and DRRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$4.00 ➝ $3.00
7/29/2025	DRRX DURECT	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRRX DURECT	$2.03M	29.67	N/A	N/A	$0.29 per share	6.69
IFRX InflaRx	$180K	343.44	N/A	N/A	$1.13 per share	0.81
MTVA MetaVia	N/A	N/A	N/A	N/A	$0.92 per share	N/A
PRLD Prelude Therapeutics	$7M	10.27	N/A	N/A	$2.39 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRRX DURECT	-$8.32M	-$0.10	0.00	N/A	N/A	-96.19%	-259.16%	-71.78%	11/12/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.80	0.00	N/A	N/A	N/A	-71.76%	-57.68%	N/A
MTVA MetaVia	-$27.59M	N/A	0.00	N/A	N/A	N/A	-212.00%	-107.21%	11/6/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.64	N/A	N/A	N/A	N/A	-106.50%	-79.07%	11/5/2025 (Estimated)

Latest MTVA, IFRX, PRLD, and DRRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	-$0.41	+$0.04	-$0.41	N/A	N/A
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	-$0.07	+$0.06	-$0.07	$0.32 million	$0.45 million
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	-$0.24	N/A	-$0.24	$0.02 million	$0.05 million
8/7/2025	Q2 2025	MTVA MetaVia	-$0.32	-$0.26	+$0.06	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRRX DURECT	N/A	0.98	0.95
IFRX InflaRx	N/A	4.10	3.78
MTVA MetaVia	N/A	2.08	2.08
PRLD Prelude Therapeutics	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRRX DURECT	28.03%
IFRX InflaRx	42.39%
MTVA MetaVia	1.37%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
DRRX DURECT	3.20%
IFRX InflaRx	16.30%
MTVA MetaVia	0.80%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRRX DURECT	80	31.05 million	30.06 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
MTVA MetaVia	8	24.20 million	24.00 million	N/A
PRLD Prelude Therapeutics	120	56.60 million	20.43 million	Optionable

MTVA, IFRX, PRLD, and DRRX Headlines

Recent News About These Companies

Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP

August 19, 2025 | msn.com

JMP Securities Cuts Prelude Therapeutics (NASDAQ:PRLD) Price Target to $3.00

August 19, 2025 | americanbankingnews.com

Prelude Cuts Q2 Losses and Costs 13%

August 14, 2025 | aol.comA

Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development

August 14, 2025 | msn.com

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | globenewswire.com

Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?

August 11, 2025 | finance.yahoo.com

Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher - Time to Buy?

July 26, 2025 | marketbeat.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, IFRX, PRLD, and DRRX Company Descriptions

DURECT NASDAQ:DRRX

$1.94 +0.02 (+1.04%)

As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

InflaRx NASDAQ:IFRX

$0.92 +0.01 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.01 (+1.10%)

As of 06:54 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

MetaVia NASDAQ:MTVA

$0.65 0.00 (-0.02%)

As of 03:57 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Prelude Therapeutics NASDAQ:PRLD

$1.27 +0.03 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$1.24 -0.03 (-2.36%)

As of 07:57 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time